Yves here. It is disheartening to see how the Democratic party and elite fondness for complex programs, best of all in eligibility rules to make the poors pay for their bennies in time and stress, then serves as a mechanism for gutting them. This article argues how drug companies are seeking to limit or end the Federal drug discount program 340B, which requires pharmaceutical companies to provide price breaks to some customers in return for Medicare and Medicaid. Their method is to misrepresent its economics, which is not hard to do since hardly anyone outside Big Pharma really understands it.
Note that sadly, consistent with that fact, this article doesn’t provide as much detail on the program itself or the distortions as I would like. I assume the author feared it would produce MEGO (My Eyes Glaze Over) in readers.
By John Arcano, a policy analyst at AIDS Healthcare Foundation.
Keep reading this article on Naked Capitalism (Yves Smith) - Blog.